List view / Grid view


AstraZeneca advances tralokinumab to Phase III in severe asthma

14 August 2014 | By AstraZeneca

AstraZeneca announced the start of the Phase III programme for tralokinumab, a potential treatment for patients with severe, inadequately controlled asthma, developed by MedImmune, the company’s global biologics research and development arm...

Allied Minds and Bristol-Myers Squibb form new enterprise to advance discoveries of biopharmaceutical innovations at leading U.S. academic research

4 August 2014 | By Bristol-Myers Squibb Company

Allied Minds and Bristol-Myers Squibb Company announced the formation of Allied-Bristol Life Sciences LLC, a new jointly owned enterprise created to identify and foster research and pre-clinical development of biopharmaceutical innovations from leading university research institutions across the U.S...